Pliant Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

PLRX 01.02.2025

SERA-AI Powered Highlights
Date of Upcoming Event:2025-01-14
Name of Upcoming Event:43rd Annual J.P. Morgan Healthcare Conference
Full Press ReleaseSEC FilingsOur PLRX Tweets

About Gravity Analytica

Recent News

  • 01.22.2025 - Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
  • 01.22.2025 - Pliant Therapeutics Appoints Delphine Imbert, Ph.D. as Chief Technical Officer
  • 01.14.2025 - 43rd Annual J.P. Morgan Healthcare Conference

Recent Filings

  • 01.22.2025 - 4 Statement of changes in beneficial ownership of securities
  • 01.22.2025 - 144 Report of proposed sale of securities
  • 11.14.2024 - SC 13G/A Statement of Beneficial Ownership by Certain Investors
PDF Version

SOUTH SAN FRANCISCO, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer, is scheduled to present at the 43rdAnnual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025 at 1:30 p.m. Pacific Time at the Westin St. Francis Hotel in San Francisco.

Interested parties may access the live webcast of this presentation by visiting the Investors & Media section of Pliant’s website atwww.PliantRx.com. The replay of this webcast will be archived for 30 days following the conclusion of the event.About Pliant Therapeutics, Inc.

Pliant Therapeutics is a late-stage biopharmaceutical company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases. Pliant's lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of αvß6 and αvß1integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. Bexotegrast has received Fast Track Designation and Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) in IPF and PSC and Orphan Drug Designation from the European Medicines Agency in IPF and PSC. Pliant has initiated BEACON-IPF, an adaptive Phase 2b/3 trial of bexotegrast in IPF. Pliant is conducting a Phase 1 study for its third clinical program, PLN-101095, a small molecule, dual-selective inhibitor of αvß8and αvß1integrins, that is being developed for the treatment of solid tumors. In addition, Pliant has received regulatory clearance for the conduct of a Phase 1 study of PLN-101325, a monoclonal antibody agonist of integrin α7β1targeting muscular dystrophies.For additional information, please visit:www.PliantRx.com. Follow us on social mediaX,LinkedIn, andFacebook.

Investor and Media Contact:

Christopher KeenanVice President, Investor Relations and Corporate CommunicationsPliant Therapeutics, Inc.ir@pliantrx.com

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com